Antiretroviral agents

Christine J. Kubin, Barbara S. Taylor, Scott M. Hammer

Producción científica: Chapter

1 Cita (Scopus)


In 1987, zidovudine became the first approved agent in the United States for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Almost 30 years later, more than 26 additional agents in six drug classes have been approved. These include nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), a fusion inhibitor (entry inhibitor), a chemokine coreceptor antagonist (entry inhibitor), integrase strand transfer inhibitors (Table 1), and pharmacokinetic enhancers. This success is the result of a prodigious effort to dissect the virus’ replication cycle and the virion’s interaction with its CD4 target cells to identify promising drug targets. It also illustrates the interdependency of the drug development process, knowledge of disease pathogenesis, and use of sensitive therapeutic monitoring tools like plasma HIV-1 RNA levels and drug resistance testing.

Idioma originalEnglish (US)
Título de la publicación alojadaClinical Virology
Número de páginas46
ISBN (versión digital)9781683670674
ISBN (versión impresa)9781555819422
EstadoPublished - mar 7 2016

ASJC Scopus subject areas

  • General Medicine
  • General Immunology and Microbiology


Profundice en los temas de investigación de 'Antiretroviral agents'. En conjunto forman una huella única.

Citar esto